Anodyne Nanotech Closed a $12.6 Million Series A to Advance Once-Weekly GLP-1 Patch into Phase I Clinical Trials
Anodyne Nanotech Inc., a clinical-stage biotechnology company simplifying chronic care through transdermal delivery, today announced the closing of a $12.6 million Series A financing. The round was led by Velocity Partners VC and co-led by Evercurious VC, with major participation from Relativity Healthcare Partners.
